Why is Tatva Chintan falling/rising?

As of 23-Sep, Tatva Chintan Pharma Chem Ltd is currently priced at 1,093.75, reflecting a decrease of 11.5 points or 1.04%. The stock has underperformed its sector by 0.48% today and has experienced a trend reversal, falling after two consecutive days of gains. It reached an intraday low of Rs 1,077.55, marking a decline of 2.51%. Over the past week, the stock has decreased by 1.12%, while it has shown a year-to-date increase of 23.90%, significantly outperforming the Sensex, which has only risen by 5.07%. Despite its positive long-term performance, the stock's delivery volume has dropped significantly, indicating falling investor participation, which may contribute to the recent price decline.
Broader market context shows that while Tatva Chintan has generated a 9.08% return over the past year, the broader market, represented by the BSE500, has seen negative returns of 4.69%. This suggests that the company has managed to outperform the market despite the recent downturn. However, the stock's performance over the last three years has been poor, with a decline of 57.15%, contrasting sharply with the Sensex's gain of 41.31%. The low debt-to-equity ratio of 0.07 times and the fact that the majority shareholders are promoters may provide some stability, but the current market dynamics and reduced trading volume are likely influencing the stock's downward movement.